Results 91 to 100 of about 4,805 (202)

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma [PDF]

, 2017
Introduction: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to poor prognosis. Within this
Bakker, Emyr, Demonacos, Constantinos, Guazzelli, Alice, Krstic-Demonacos, Marija, Mutti, Luciano, Tian, Kun   +5 more
core   +2 more sources

Extramedullary Disease—Achilles Heel in Myeloma?

American Journal of Hematology, Volume 101, Issue 3, Page 521-536, March 2026.
ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar, Joshua Richter, Saad Z. Usmani, Yael C. Cohen, Jing Christine Ye, María‐Victoria Mateos, Vania Hungria, Elena Zamagni   +7 more
wiley   +1 more source

Elranatamab for Treatment of Multiple Myeloma With Central Nervous Involvement Refractory to Other Interventions

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Background Plasma cell leukemia and central nervous system involvement are two poor prognostic factors in myeloma, and such patients are often excluded from clinical trials. Case A 59‐year‐old patient with primary plasma cell leukemia developed leptomeningeal CNS disease following autologous transplant.
Kelley Julian, Briana Peterson, Ghulam Rehman Mohyuddin   +2 more
wiley   +1 more source

Adverse events reporting of XPO1 inhibitor - selinexor: a real-word analysis from FAERS database

Scientific Reports
As the world's first oral nuclear export inhibitor, selinexor is increasingly being used in clinical applications for malignant tumors. However, there is no extensive exploration on selinexor's adverse events (ADEs), necessitating a real-word assessment ...
Yi Liu, Runyu Yang, Hui Feng, Yue Du, Bingyu Yang, Mengyao Zhang, Pengcheng He, Bohan Ma, Fan Niu   +8 more
doaj   +1 more source

Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine

Frontiers in Oncology
BackgroundAtypical chronic myeloid leukemia (aCML) is a BCR::ABL1 negative myelodysplastic/myeloproliferative neoplasm with poor overall survival.
Lu Liu, Xiaofeng Song, Wenhao Dong, Zhao Li, Dongmei Guo   +4 more
doaj   +1 more source

Successful Treatment of Refractory Sweet's Syndrome With Adalimumab in a Myelodysplastic Syndrome Patient

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT We report a 69‐year‐old man diagnosed as myelodysplastic syndrome and administrated with azacitidine and selinexor treatment. Then he was revealed high fever and multiple tender erythematous papules involving his mouth, back, upper and lower extremities, which were diagnosed as Sweet's syndrome by skin biopsy.
Liya Ma, Yaojia Shen, Jie Chang, Shanshan Suo, Lu Wang, Weifang Zhu, Jianjun Qiao, Hongyan Tong   +7 more
wiley   +1 more source

Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor

Current Oncology
Best practice (BP) in cancer care consists of a multifaceted approach comprising individualized treatment plans, evidence-based medicine, the optimal use of supportive care and patient education.
Lucio N. Gordan, David Ray, Stephen C. Ijioma, George Dranitsaris, Amanda Warner, Trevor Heritage, Matthew Fink, David Wenk, Paul Chadwick, Natasha Khrystolubova, Shachar Peles   +10 more
doaj   +1 more source

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial

Haematologica, 2018
Targeted therapies against FLT3-mutated acute myeloid leukemias have shown limited clinical efficacy primarily because of the acquisition of secondary mutations in FLT3 and persistent activation of downstream pro-survival pathways such as MEK/ERK, PI3K ...
Weiguo Zhang, Charlie Ly, Jo Ishizawa, Hong Mu, Vivian Ruvolo, Sharon Shacham, Naval Daver, Michael Andreeff   +7 more
doaj   +1 more source

Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Refractory Multiple Myeloma

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT This study demonstrates the application of a model based meta analysis (MBMA) framework to characterize the safety and efficacy profiles of therapies in relapsed and refractory multiple myeloma (RRMM). Published clinical trial data were analyzed to evaluate the incidence of Grade ≥ 3 neutropenia and overall response rate (ORR), providing a ...
Zeel Shah, Clifton M. Anderson, Kevin D. McCormick, Celeste Vallejo, William Duncan, Chuanpu Hu, Jian Zhou, Alexander V. Ratushny, Anna G. Kondic   +8 more
wiley   +1 more source

A CRM1 Inhibitor Alleviates Cardiac Hypertrophy and Increases the Nuclear Distribution of NT-PGC-1α in NRVMs

Frontiers in Pharmacology, 2019
Chromosomal maintenance 1 (CRM1) inhibitors display antihypertrophic effects and control protein trafficking between the nucleus and the cytoplasm. PGC-1α (peroxisome proliferator-activated receptor gamma coactivator-1alpha) is a type of transcriptional ...
Zuheng Liu, Zuheng Liu, Haiping Tian, Haiping Tian, Haiping Tian, Jinghai Hua, Jinghai Hua, Wanqiang Cai, Wanqiang Cai, Yujia Bai, Yujia Bai, Qiong Zhan, Qiong Zhan, Wenyan Lai, Wenyan Lai, Qingchun Zeng, Qingchun Zeng, Hao Ren, Hao Ren, Dingli Xu, Dingli Xu   +20 more
doaj   +1 more source